About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, October 8th, 2014

The QualityStocks
Daily Stock List


ICTV Brands, Inc. (ICTV)

Today we are reporting on ICTV Brands, Inc. (ICTV), here at the QualityStocks Daily Newsletter.

ICTV Brands, Inc. (ICTV) sells a variety of health and beauty products via infomercials and other channels largely in the U.S. The Company is a direct response marketing and branding company focusing on the health, wellness, and beauty sector. While its products are sold mainly in the U.S., they are also available in more than 35 countries. ICTV Brands lists on the OTCQB. Founded in 1993, the Company has its headquarters in Wayne, Pennsylvania.

A component of ICTV’s strategy is to create a portfolio of uniquely branded, high profile products focused on the health and beauty markets. Its products include DermaWand, which is a skin care device that reduces the appearance of fine lines and wrinkles. It also helps improves skin tone and texture.

The Company’s products also include DermaVitál. This is a professional quality skin care range that effects premier hydration. In addition, it offers CoralActives. This is a line of acne treatment and skin cleansing products. 

ICTV Brands employs a distinct marketing strategy and multi-channel distribution model. This is to develop, market and sell products by way of direct response television (DRTV), Internet/digital, e-commerce, live television shopping, as well as retail.

At the end of September, ICTV Brands announced that three new brands are ready for marketing. These are Jidue, the above-mentioned CoralActives, and Derma Brilliance. Jidue is a facial massager, which works through 18 uniquely positioned pulsating nodes that stimulates the four key pressure points around the eye to increase facial blood circulation and lymph flow. The design of Jidue is to help alleviate eye fatigue, pain, and stress and sinus pain.

CoralActives is the Company’s new product in the acne treatment and skin cleansing market. CoralActives contains more than two times the active acne fighting ingredient, benzoyl peroxide, of the leading brands. It combines the natural anti-inflammatory benefits of sea whip coral extract.

Derma Brilliance is a cosmetic system in the growing skin-polishing sector of the skin-care device market. Derma Brilliance will be a "razor/razor blade continuity model". It will be led by a hand held rechargeable device and optimized by a consumable micronized diamonds and garnets skin cream formula, both of which are patented. 

ICTV Brands, Inc. (ICTV), closed Wednesday's trading session at $0.70, down 2.78%, on 48,550 volume with 23 trades. The average volume for the last 60 days is 114,467 and the stock's 52-week low/high is $0.22/$1.08.

Islet Sciences, Inc. (ISLT)

TheMicrocapNews, FeedBlitz, Prof. Stocks, and Proactivecrg reported earlier on Islet Sciences, Inc. (ISLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Islet Sciences, Inc. is a biopharmaceutical company developing novel technologies for the diagnosis and treatment of patients suffering from metabolic diseases. The Company has entered into a number of collaborations with prestigious diabetes research groups. These collaborations allow Islet to pursue a broad array of cell transplantation technologies. Islet Sciences is based in Raleigh, North Carolina.

In December 2013, Islet Sciences reported that it is consolidating operations centrally under a one-company/one-pipeline strategy, as it moves away from independently managed programs. Its corporate mission is to become the foremost innovator, developer, as well as provider of therapeutics and diagnostics for diabetes.

The Company is developing an encapsulated islet cell transplantation therapy for the treatment of type 1 or insulin-dependent diabetes. In addition, it is developing first-in-class immune-modulating small molecule IL-12 inhibitors, which protect insulin-producing beta-cells from cytokines responsible for cell destruction. Furthermore, Islet is developing a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes.

Recently, Islet Sciences announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Lisofylline Analogs and Methods for Use."  The new patent (U.S #13/477,613) will extend coverage to include a considerably broader range of chemical compounds that Islet may develop as immune-modulating drugs targeting an inflammatory pathway involved in several important diseases. These include diabetes and non-alcoholic steatohepatitis (NASH).

On October 1, 2014, Islet Sciences and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma (BHV), jointly announced that, in line with the Letter of Intent (LOI) entered into by Islet Sciences and BHV on March 12, 2014, they have entered into a merger agreement, which will combine the operations and development pipelines of the two companies.

Upon closing of the acquisition of BHV, the combined organization will be named Avogenx, Inc. It will continue to operate under the leadership of the current Islet Sciences management. BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate (remogliflozin) for type 2 diabetes and non-alcoholic steatohepatitis (NASH).

Islet Sciences, Inc. (ISLT), closed Wednesday's trading session at $0.2449, up 16.62%, on 17,700 volume with 3 trades. The average volume for the last 60 days is 36,565 and the stock's 52-week low/high is $0.1051/$1.11.

Sunshine Biopharma, Inc. (SBFM)

PennyStocks24, StockHideout, 007 Stock Chat, Stock Roach, and PennyStockSpy reported earlier on Sunshine Biopharma, Inc. (SBFM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Based in Montreal, Quebec, Sunshine Biopharma, Inc. is a pharmaceutical company that lists on the OTC Markets’ OTCQB. It is focusing on the research, development, and commercialization of drugs for the treatment of different forms of cancer.  The Company’s commitment is to developing novel therapies for the treatment of different forms of aggressive cancer types. Its initial drug candidate, Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer cell lines. These include breast cancer (MCF-7/MDR), small-cell lung cancer (H69AR), uterine carcinoma (MES-SA/Dx5) and pancreatic cancer (Panc-1).

Sunshine Biopharma’s Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer.  Adva-27a is now in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.

Sunshine Biopharma entered into a collaboration agreement in January 2011 with Binghamton University (State University of New York at Binghamton, New York). This agreement is to conduct certain research and development activities intended at advancing the Company’s lead compound, Adva-27a, through various stages of preclinical development.

In June 2011, Sunshine Biopharma entered into a Clinical Trials Agreement with The Jewish General Hospital, one of McGill University’s Hospital Centers, to conduct certain research and development activities and advance Sunshine’s Adva-27a through the different stages of preclinical studies and Phase I clinical trials on multidrug resistant breast cancer patients. The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal.

Sunshine Biopharma announced in April that it resolved the two isomeric forms of its Adva-27a, and accordingly the specific activity of the drug candidate has increased 9.5-fold. It had previously announced that the concentration at which Adva-27a inhibited 50 percent of the activity of Topoisomerase II (IC50) was 13.7 micromolar. Because of this development, Adva-27a's IC50 has dropped 9.5-fold, to 1.44 micromolar. Sunshine Biopharma said that this suggests that significantly lower quantities of the drug can be used to attain the same effect.

In July, Sunshine Biopharma announced that it formed Sunshine Biopharma Canada Inc., a Canadian wholly-owned subsidiary. This subsidiary will conduct pharmaceutical business in Canada and elsewhere worldwide. 

In September, Sunshine Biopharma announced that it is presently negotiating with several Contract Research Organizations (CRO's). The intention is to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a. A master drug file contains all of the information that regulatory agencies need as part of the drug development and approval process. This information includes preclinical data, GMP manufacturing process, large animal studies and human trials.

Sunshine Biopharma, Inc. (SBFM), closed Wednesday's trading session at $0.06, even for the day, on 20,250 volume with 5 trades. The average volume for the last 60 days is 40,164 and the stock's 52-week low/high is $0.0452/$0.27.

Repro-Med Systems, Inc. (REPR)

SmallCapVoice and PennyTrader Publisher reported previously on Repro-Med Systems, Inc. (REPR), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

OTCQB listed Repro-Med Systems, Inc. d/b/a RMS Medical Products provides precision medical devices. Incorporated in 1980, it is a foremost developer and manufacturer of medical devices and supplies. RMS manufactures medical devices used in emergency care, hospital settings, nursing homes, other medical facilities and home care. RMS maintains its own sales staff and sells its products via distributors in the U.S. and several other nations.

Repro-Med Systems’ main products include the HIgH-Flo™ Subcutaneous Safety Needle Sets. The Company’s main products additionally include the FREEDOM60® Syringe Infusion Pump, FREEDOM60® Precision™ Flow Rate Tubing, and RES-Q-VAC Hand Held Medical Suction. Repro-Med holds a number of patents related to products it has developed and is manufacturing.

The design of its FREEDOM60® Syringe Infusion Pump is for ambulatory medication infusions. For the home care patient, FREEDOM60® is a user-friendly lightweight mechanical pump using a 60cc syringe, completely portable, cost effective and maintenance free. There are no batteries to replace and no unwieldy IV pole. For the infusion professional, FREEDOM60® delivers accurate infusion rates and uniform flow profiles providing consistent transfer of medication.

The RMS HIgH-Flo™ Subcutaneous Safety Needle Set underwent development as an improvement in performance and safety over like devices. Repro-Med Systems’ design enables drug flows, which are the same or faster than those attained with larger gauge needles now on the market. It is offered in needle lengths of 4mm, 6mm, 9mm, 12mm and 14mm. The sets are available in combinations for single, double, triple, quadruple, penta and hexa infusions. Needle sets use a Low Residual "Y" Connector. The sets can deliver to as many as eight infusion sites.

Since 1986, Repro-Med has owned and marketed the Gyneco product line. This includes the Masterson Endometrial Biopsy Kit used for in-office biopsy sampling procedures, and the Thermal Cautery System used for tubal ligation procedures.

Recently, Repro-Med Systems (d/b/a RMS Medical Products) announced that it secured growth capital commitments from the Horton Capital Partners Fund (an institutional investor based in Philadelphia, Pennsylvania). Horton Capital agreed to purchase 1 million shares at $0.288 per share and received warrants to purchase an additional 1 million shares should the share price appreciate to higher than $0.45. The proceeds will be used to fund future growth. Repro-Med is working to execute its plan and leverage major opportunities being presented to it in the infusion market. 

Repro-Med Systems, Inc. (REPR), closed Wednesday's trading session at $0.38, even for the day, on 105,437 volume with 22 trades. The average volume for the last 60 days is 36,048 and the stock's 52-week low/high is $0.156/$0.665.

Petrosonic Energy, Inc. (PSON)

TopPennyStockMovers and Trade of the Week reported recently on Petrosonic Energy, Inc. (PSON), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Founded in 2008, Petrosonic Energy, Inc. engages in heavy oil upgrading and related technologies. At present, its principal focus is to provide technologies that upgrade heavy oil economically and in an environmentally friendly manner. Petrosonic has acquired 100 percent of the Intellectual Property (IP) for the Sonoprocess™ Technology, and an established processing plant. Petrosonic Energy lists on the OTC Markets’ OTCQB. The Company has its headquarters in Calgary, Alberta.  

Petrosonic Energy is in an advanced stage of development regarding applications for heavy oil sands separation from oil sands and ecology pits, and oil separations from cuttings. The Company’s patented Sonoprocess™ uses cleantech sonic energy to de-asphalt heavy oil at a much smaller scale and lower capital costs than conventional upgraders. It does so without the use of water or the release of emissions in the atmosphere. Petrosonic’s core sonic de-asphalting technology is a proprietary industrial scale sonic reactor. It transfers sonic energy on an industrial scale to physical, chemical, or biological processes.

The Company previously reported that the engineering firm, Gas Liquids Engineering of Calgary completed third-party sonification tests in the Richmond, British Columbia facility. The results were sent to a third party lab, Maxxam, in Calgary for separation and solvent recovery lab simulation. The results will be used to finalize the engineering and estimates of the asphaltene separation and solvent recovery equipment.  Additionally, Petrosonic Energy reported that its emulsion testing process in Albania is continuing successfully.

Petrosonic Energy’s first Heavy Oil Processing facility will deliver cash flow and commercialization of the Sonoprocess™ on an ongoing basis. The Company is commercializing its patented Sonoprocess Heavy Oil Upgrading Technology via its wholly-owned subsidiaries and joint ventures (JVs) with third parties.

This past June, Petrosonic Energy reported that it successfully completed a third party engineering feasibility analysis and validation of its proprietary Sonoprocess™ sonic de-asphalting technology with Gas Liquids Engineering of Calgary. The sonication tests and the subsequent analysis conducted by Maxxam confirmed the capability of Petrosonic Energy's technology to sonicate heavy oil using a paraffinic solvent to separate a heavy metals concentrated asphaltenes and resins fraction while producing a higher quality oil with increased API rating values.

Furthermore, in July, Petrosonic Energy announced it has developed a new solution to its sonic de-asphalting process. This solution will enable the process to use propane/LPGs to de-asphalt heavy oils. LPGs/propane are more common and less expensive solvents. The new solution is called Sono Hi-P™. It was developed in collaboration with Gas Liquids Engineering of Calgary, which carried out the full engineering and validation of the Sonoprocess™. Petrosonic has filed a patent for the new solution.

Petrosonic Energy, Inc. (PSON), closed Wednesday's trading session at $0.1999, down 2.49%, on 374,241 volume with 64 trades. The average volume for the last 60 days is 167,222 and the stock's 52-week low/high is $0.10/$0.35.

PMX Communities, Inc. (PMXO)

Pumps and Dumps, Greenbackers, AimHighProfits, 007 Stock Chat, PennyStockSpy, and SmallCap Fortunes reported earlier on PMX Communities, Inc. (PMXO), and we highlight the Company also, here at the QualityStocks Daily Newsletter.

PMX Communities, Inc. is a precious metals incubation company based in Boca Raton, Florida. It is a holding company for wholly-owned subsidiaries, which focus in the gold industry. PMX Gold Bullion Sales, Inc., and PMX Gold are wholly owned subsidiaries of PMX Communities.  PMX Gold Bullion Sales and PMX Gold are working together to launch gold bullion terminals globally. The letters “PMX” in the Company’s name denote “Precious Metals Exchange.”
PMX’s chief business purpose is incubating and developing prospects within the precious metals and mining industries. Its mission is to create a distinctive precious metals company that manufactures customized dispensing terminals filled with gold and to sell .9999 Gold bars and .9999 Gold coins to the public. The Company’s vision is to be recognized as the leading provider of custom .9999 fine gold bars and coins for consumption and long-term investment purposes.

PMX has launched the first gold dispensing terminal in the U.S.  PMX Gold Bullion Sales launched the MGIV gold terminal in Town Center, Boca Raton, Florida in January 2013. The Company is combining on-demand delivery of certified .9999 fine gold investment products from its gold terminals and real-time pricing. The MGIV gold terminal is a specialty gold dispensing machine. Consumers can buy different denominations of fine gold bullion bars and coins with a swipe of their global credit and debit cards.

PMX Gold focuses on the marketing of opportunities involving gold bullion bars and coins. In addition, PMX Gold Mineral Options Trading & Mining Development, Inc. targets potential mining properties in South America.

PMX Communities announced in February 2014 the diversification of its product line of dispensing machines with the introduction of the LXIV Marijuana terminal. The LXIV will be similar in appearance to the Company’s precious metals terminal successfully tested in Florida in 2013. 

PMX Communities has subsequently expanded the LXIV Marijuana terminal target footprint to 18 states. It has centered on 18 states for the LXIV Marijuana terminal to launch with a strong sales force throughout the nation. PMX Communities is not looking to become a vertical medical dispensary. The LXIV focus is being a delivery system with many marijuana products to enhance a consumer's experience at a medical or retail marijuana dispensary.

At the end of September, PMX Communities and PMX Gold Bullion Sales announced getting set for the Bud Box paraphernalia terminal launch. PMX Communities is preparing to launch its paraphernalia dispensing machines. The Bud Boxes will dispense metal-hinged boxes with a varied product line of smoking pipes, rolling paper, hemp wicks, screens, vaporizers, candles, incense cones and sticks, ash catchers, aromatherapy balms, and eco-friendly products.

PMX Communities, Inc. (PMXO), closed Wednesday's trading session at $0.0076, even for the day. The average volume for the last 60 days is 69,046 and the stock's 52-week low/high is $0.0015/$0.084.

Searchlight Minerals Corp. (SRCH)

SmarTrend Newsletters reported previously on Searchlight Minerals Corp. (SRCH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Searchlight Minerals Corp. engages in the acquisition and exploration of mineral properties and slag reprocessing projects. An exploration stage company, it is concentrating on the acquisition and development of projects in the southwestern United States. It holds interests in the Clarkdale Slag Project and the Searchlight Gold Project. OTCQB listed Searchlight Minerals is based in Henderson, Nevada.

The Clarkdale Slag Project is in Clarkdale, Arizona. It is a reclamation project to recover precious and base metals from the reprocessing of slag produced from the smelting of copper ore mined at the United Verde Copper Mine in Jerome, Arizona. The Searchlight Gold Project involves exploration for precious metals on mining claims near Searchlight, Nevada. The Clarkdale Slag Project is the more advanced of two ongoing projects.

The Searchlight Gold Project is an early-stage gold exploration project on 3,200 acres located roughly 50 miles south of Las Vegas, Nevada.  To conserve its cash and resources, Searchlight Minerals has decided to postpone further exploration on its Searchlight Gold Project until the Company is better able to determine the feasibility of its Clarkdale Slag Project.

Upon deciding to resume its exploration program, work on the project site will be limited to the scope within the Plan of Operations. To perform any additional drilling or mining on the project, Searchlight would need to submit a new application to the Bureau of Land Management (BLM) for approval before the start of any such additional activities.

Searchlight Minerals announced this past May significant technical achievements in gold and iron recovery at its Clarkdale Slag Project. The achievements include, but are not limited to, the determination of precise nature of the gold contained in the slag material; the addition of a high temperature pre-treatment step that aids in the recovery of the gold and provides a saleable iron by-product; and up to a 60 percent extraction of metallic gold from fire assay of ion exchange resin. Searchlight believes that the project is commercially viable, if repeatable, at current results, based on these achievements.

Searchlight Minerals Corp. (SRCH), closed Wednesday's trading session at $0.171, down 2.06%, on 11,000 volume with 1 trade. The average volume for the last 60 days is 44,384 and the stock's 52-week low/high is $0.151/$0.43.


The QualityStocks
Company Corner


VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.50, up 16.67%, on 200 volume with 2 trades. The stock’s average daily volume over the past 60 days is 72, and its 52-week low/high is $5.00/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives Notice of Allowance for Canadian Patent, Further Expanding Stem Cell Technology Platform

VistaGen Announces Reverse Stock Split

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.41, up 5.10%, on 203,834 volume with 68 trades. The stock’s average daily volume over the past 60 days is 70,122, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. Update -- MRSA and Lung Cancer Device Development

Zenosense, Inc. Begins Development of Lung Cancer Detection Device

Zenosense, Inc. Highlights Recent Media Coverage of MRSA

Armco Metals Holdings, Inc. (AMCO)

The QualityStocks Daily Newsletter would like to spotlight Armco Metals Holdings, Inc. (AMCO). Today, Armco Metals Holdings, Inc. closed trading at $0.1395, up 11.60%, on 11,214 volume with 27 trades. The stock’s average daily volume over the past 60 days is 152,835, and its 52-week low/high is $0.1001/$0.58.

Armco Metals Holdings, Inc. (AMCO), since its founding 10 years ago, has tirelessly worked to create low-cost, high-quality solutions to meet steel industry demands and achieve its goal to become the largest scrap steel recycler in China. The company operates through five subsidiaries located in key regions throughout the country to source, import, process, and distribute quality, environmentally friendly recycled scrap steel, as well as metal and non-ferrous metal ore.

Subsidiaries Armco Metals International, Ltd., Armco (Lianyungang) Renewable Metals, Inc., Armet (Lianyungang) Holdings, Inc., Henan Armco & Metawise Trading Co., Ltd., Armco Metals (Shanghai) Holding, Ltd. support Armco Metal’s overarching corporate mission and operate to provide the country’s steel production industry with sustainable, responsible solutions to its material needs. Aligned with China’s green initiatives, Armco Metals and its subsidiaries are helping the government reach its scrap metal consumption goal of 20% by 2015.

Leveraging long-standing relationships with more than 10 international metal suppliers, more than 100 small- and medium-sized Chinese steel production companies, and some of the country’s large state-run foundries, Armco Metals benefits from a steady and dependable supply of demand for the company’s high-quality product known for excellent market values.

Armco Metals’ management team has established a unique approach to business and environment by providing responsible solutions based on environmentally friendly practices; reliable, cost-effective sourcing; and quality metal products. Backed by more than 10 years of industry experience, company executives have successfully positioned the company as credible, dependable partner for customers, suppliers, and investors within the steel production market. Disclaimer

Armco Metals Holdings, Inc. Company Blog

Armco Metals Holdings, Inc. News:

Armco Metals Enters Into an Agreement With a Chile Supplier for Woodchips Purchase

Armco Metals Holdings Announces Financial Results for the Second Quarter of 2014

China's Ministry of Industry and Information Technology Approves Subsidiary

Mobile Lads Corp. (MOBO)

The QualityStocks Daily Newsletter would like to spotlight Mobile Lads Corp. (MOBO). Today, Mobile Lads Corp. closed trading at $0.34, up 13.33%, on 10,046 volume with 8 trades. The stock’s average daily volume over the past 60 days is 29,966, and its 52-week low/high is $0.1201/$0.40.

Mobile Lads Corp. (MOBO) designs and delivers secure, wide-area wireless transaction software solutions for the consumer finance, web and health payment processing sectors. The company’s solutions provide streamlined, continuous access to time-sensitive information and data on multiple network standards. Mobile Lads’ products and services, offered through its Xtreme Mobility division, centers on three core technologies that simplify and secure wireless communications: xmVerify, xmBilling, and xmOne.

xmVerify is a real-time mobile transaction security service that prevents credit card fraud by giving users control over the authorization process when making purchases. Using one of the best cryptographic services, and in compliance with most all available platforms, xmVerify sends a transaction authorization request directly to the user’s mobile phone to ensure authenticity.

xmBilling is a mobile platform that provides customers with a convenient and secure way to review and authorize automatic billing transactions, easing the challenges of automated and volume-based billing. The system sends the user a text message with a URL leading to an online e-bill where they can review details of the bill and authorize the payment via credit card with the use of their PIN number.

The xmOne mobile platform provides an array of encrypted mobile services, including top-up, payment processing, emergency notification and marketing, ideal for students and higher education facilities. xmOne interfaces with a school’s existing campus card account system to enable students to perform a variety of banking transactions from their cell phones. The university or college benefits from increased usage of the flex-dollar ecosystem, reduces overhead from ADMs, and can be customized to each school’s individual brand.

Mobile Lads is guided by a management team with a unique blend of in-depth technical expertise in wireless channel communications and a solid background in business strategy and consumer analysis. The company’s vision is to grow as a leading-edge wireless solution provider by enabling innovative, wide-area communication solutions on a global scale. Disclaimer

Mobile Lads Corp. Company Blog

Mobile Lads Corp. News:

Mobile Lads Acquires Innovative Online Coupon Platform, CouBox

Mobile Lads Signs Reseller Agreement With Smart Mobile Rewards

Mobile Lads Signs Letter of Intent for Xtreme Mobility Software Acquisition

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.021, up 5.00%, on 4,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 29,706, and its 52-week low/high is $0.0005/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

Panther Energy Changes Name to Falcon Crest Energy

Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.1299, off by 0.08%, on 26,224 volume with 7 trades. The stock’s average daily volume over the past 60 days is 48,781, and its 52-week low/high is $0.031/$0.24.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling Group Holdings, Inc. President David Saba, to Be Interviewed LIVE on Clear Channel Business Talk Radio -- (September 30, 2014)

Sibling's Blended Schools Network Division Offers Special Education Professional Development for All Educators

Sibling's BSN Division Launches Teacher Professional Development on Udemy Global Marketplace

Ecrypt Technologies, Inc. (ECRY)

The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.134, even for the day. The stock’s average daily volume over the past 60 days is 7,494 and its 52-week low/high is $0.09/$0.179.

Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.

Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.

The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.

Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer

Ecrypt Technologies, Inc. Blog

Ecrypt Technologies, Inc. News:

Ecrypt Technologies Inc.'s Chief Executive Officer, Dr. Thomas A. Cellucci, is the First American Elected to EECSA's Board

Safe America Appoints Ecrypt CEO to Head Drive

Ecrypt Technologies and Cicada Security Technology Enter into a Marketing Alliance


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Information Solutions Group


Streetwise Reports



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251